Category «Uncategorized»

LNS-8801 (SRR G-1)

It’s only fair to share…   LNS-8801 (SRR G-1) CAS  925419-53-0 Chemokine receptor-like 2 agonist C21 H18 Br N O3, 412.28 Ethanone, 1-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]- 1-((3aS,4R,9bR)-4-(6-bromobenzo[d][1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)ethan-1-one 1-[(3aS,4R,9bR)-4-(6-Bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]ethanone G 1 G 1 (estrogen receptor agonist)   Linnaeus Therapeutics Inc NOTE 1-((3aR,4S,9bR)-4-(6-bromobenzo[d][1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)ethan-1-one (RSS G-1 or LNS8812)  Novel crystalline forms of an enantiomerically purified LNS-8801 (SRR G-1), or a derivative useful for treating cancer, …

CC-90010

It’s only fair to share… CC-90010 C21 H21 N O4 S, 383.46 CAS 1706738-98-8 1(2H)-Isoquinolinone, 4-[2-(cyclopropylmethoxy)-5-(methylsulfonyl)phenyl]-2-methyl- 4-[2-(Cyclopropylmethoxy)-5-(methylsulfonyl)phenyl]-2-methyl-1(2H)-isoquinolinone 4-[2-(Cyclopropylmethoxy)-5-(methanesulfonyl)phenyl]-2-methylisoquinolin-1(2H)-one 4-[2-(Cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one Quanticel Pharmaceuticals Inc, Michael John BennettJuan Manuel BetancortAmogh BoloorStephen W. KaldorJeffrey Alan StaffordJames Marvin Veal Celgene  (now a wholly owned subsidiary of  Bristol-Myers Squibb ) , following its acquisition of  Quanticel , is developing CC-90010, an oral inhibitor of BET (bromodomain and extraterminal) …

Delgocitinib

It’s only fair to share… Delgocitinib デルゴシチニブ 3-[(3S,4R)-3-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile 1,6-Diazaspiro(3.4)octane-1-propanenitrile, 3-methyl-beta-oxo-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (3S,4R)- 3-((3S,4R)-3-methyl-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1,6-diazaspiro(3.4)octan-1-yl)-3-oxopropanenitrile   Formula C16H18N6O CAS 1263774-59-9 Mol weight 310.3537 Approved, Japan 2020, Corectim, 2020/1/23, atopic dermatitis, Japan Tobacco (JT) Torii UNII-9L0Q8KK220, JTE-052, LP-0133, ROH-201, 9L0Q8KK220, LEO 124249A, LEO 124249, HY-109053 CS-0031558, D11046, GTPL9619, JTE-052A, JTE052 Delgocitinib, also known as LEO-124249 and JTE052, is a potent and selective JAK inhibitor. JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent …

Dotinurad ドチヌラド

It’s only fair to share…   Dotinurad ドチヌラド (3,5-dichloro-4-hydroxyphenyl)-(1,1-dioxo-2H-1,3-benzothiazol-3-yl)methanone Formula C14H9Cl2NO4S CAS 1285572-51-1 Mol weight 358.1966 PMDA, Urece, APROVED JAPAN 2020/1/23, Antihyperuricemic 305EB53128UNII-305EB53128 1285572-51-1, VOFLAIHEELWYGO-UHFFFAOYSA-N HY-109031 CS-0030545 Dotinurad is a urate transporter inhibitor. Patents WO 2011040449   https://patents.google.com/patent/WO2011040449A1/en Uric acid is produced by metabolizing a purine produced by the degradation of a nucleic acid in the body and adenosine …

IIIM-290

It’s only fair to share…   IIIM-290 4H-1-Benzopyran-4-one, 2-[2-(2,6-dichlorophenyl)ethenyl]-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]- Molecular Weight 462.32 Formula C₂₃H₂₁Cl₂NO₅ CAS No. 2213468-64-3 CSIR-IIIM Jammu has filed an IND Application of “IIIM-290” to Drug Controller General of India for conducting Phase I/Phase II clinical trial of its capsule formulation in patients with locally advanced or metastatic pancreatic cancer. This IND candidate …

Zanubrutinib, ザヌブルチニブ , занубрутиниб , زانوبروتينيب ,

It’s only fair to share…   Zanubrutinib, BGB-3111 Formula C27H29N5O3 CAS 1691249-45-2 Mol weight 471.5509 FDA , 2019/11/14, Brukinsa ザヌブルチニブ , занубрутиниб [Russian] زانوبروتينيب [Arabic] (7S)-7-(1-Acryloyl-4-piperidinyl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 4,5,6,7-tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-, (7S)- Antineoplastic, Bruton’s tyrosine kinase inhibitor, Mantle cell lymphoma Zanubrutinib, sold under the brand name Brukinsa, is for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.[3] …

ENCORAFENIB, エンコラフェニブ

It’s only fair to share… ENCORAFENIB, エンコラフェニブ UNII:8L7891MRB6 Formula:C22H27ClFN7O4S, Average: 540.01 1269440-17-6 BRAFTOVI NVP-LGX818 NVP-LGX-818-NXA NVP-LGX818-NXA ENCORAFENIB [USAN] ENCORAFENIB [WHO-DD] ENCORAFENIB ENCORAFENIB [INN] METHYL N-((2S)-1-((4-(3-(5-CHLORO-2-FLUORO-3-(METHANESULFONAMIDO)PHENYL)(-1-(PROPAN-2-YL)-1H-PYRAZOL-4-YL(PYRIMIDIN-2-YL)AMINO)PROPAN-2-YL)CARBAMATE CARBAMIC ACID, N-((1S)-2-((4-(3-(5-CHLORO-2-FLUORO-3-((METHYLSULFONYL)AMINO)PHENYL)-1-(1-METHYLETHYL)-1H-PYRAZOL-4-YL)-2-PYRIMIDINYL)AMINO)-1-METHYLETHYL)-, METHYL ESTER LGX818 LGX-818 Encorafenib, also known as BRAFTOVI, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic …

GRAPIPRANT

It’s only fair to share… GRAPIPRANT Molecular FormulaC26H29N5O3S Average mass491.605 Da CAS 415903-37-6 UNII-J9F5ZPH7NB, CJ 023423, CJ-023423, Phase II, Arrys Therapeutics, CANCER, PAIN, AskAt Phase II,  N-{2-[4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl}-N’-[(4-methylphenyl)sulfonyl]urea RQ-00000007, MR10A7 9763 AAT-007 Benzenesulfonamide, N-[[[2-[4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]amino]carbonyl]-4-methyl- CJ-023,423 N-[[[2-[4-(2-Ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]amino]carbonyl]-4-methylbenzenesulfonamide 1-[2-[4-(2-Ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea 2-Ethyl-4,6-dimethyl-1-[4-[2-[[[[(4-methylphenyl)sulfonyl]amino]carbonyl]amino]ethyl]phenyl]-1H-imidazo[4,5-c]pyridine AAT 007 CJ 023423 Grapiprant MR 10A7 RQ 00000007 RQ 7 Synonyms and Mappings 415903-37-6 GRAPIPRANT [GREEN BOOK] CJ-023 GRAPIPRANT [INN] GRAPIPRANT [WHO-DD] MR-10A7 …

Brilliant blue G , ブリリアントブルーG ,

It’s only fair to share…   Brilliant blue G FDA 2019, 12/20/2019, TISSUEBLUE, New Drug Application (NDA): 209569 Company: DUTCH OPHTHALMIC, PRIORITY; Orphan OPQ recommends APPROVAL of NDA 209569 for commercialization of TissueBlue (Brilliant Blue G Ophthalmic Solution), 0.025% Neuroprotectant sodium;3-[[4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-N-ethyl-3-methylanilino]methyl]benzenesulfonate Formula C47H48N3O7S2. Na CAS 6104-58-1 Mol weight 854.0197 ブリリアントブルーG, C.I. Acid Blue 90 UNII-M1ZRX790SI M1ZRX790SI 6104-58-1 Brilliant Blue G Derma …

Fluorodopa F 18, フルオロドパ (18F), флуородопа (18F) , فلورودوبا (18F) , 氟[18F]多巴 ,

It’s only fair to share… Fluorodopa F 18 2019/10/10, fda 2019, Formula C9H10FNO4 Cas 92812-82-3 Mol weight 215.1784 Diagnostic aid (brain imaging), Radioactive agent, for use in positron emission tomography (PET) CAS 92812-82-3 フルオロドパ (18F) L-6-(18F)Fluoro-DOPA L-Tyrosine, 2-fluoro-18F-5-hydroxy- [ACD/Index Name] флуородопа (18F) [Russian] [INN] فلورودوبا (18F) [Arabic] [INN] 氟[18F]多巴 [Chinese] [INN] ((18)F)FDOPA 2-(fluoro-(18)F)-5-hydroxy-L-tyrosine 2-(Fluoro-18F)-5-hydroxy-L-tyrosine 2-(Fluoro-18F)-L-DOPA 2C598205QX 6-((18)F)fluoro-L-DOPA 6-(18F)Fluoro-L-DOPA 6692 (18F)FDOPA 2-((18)F)fluoro-5-hydroxy-L-tyrosine Fluorodopa, also …